Skip to content
Joints & Immunity — JAK inhibitorsATC L04AA44

Upadacitinib

Prescription only

Selective JAK1 inhibitor for arthritis, eczema and inflammatory bowel disease.

Starts working
Weeks
Half-life
About 8–14 hours
In use since
—
Pregnancy
Usually avoided

Overview

Upadacitinib is a once-daily JAK1 inhibitor used for rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, atopic dermatitis and IBD. JAK inhibitor warnings apply.

How it works

Calms immune signalling inside cells.

Upadacitinib belongs to the JAK inhibitors. How JAK inhibitors work: block JAK enzymes that pass messages from several inflammation signals into immune cells.

Uses

  • Rheumatoid arthritis
  • Psoriatic arthritis
  • Atopic dermatitis (eczema)
  • Crohn's disease
  • Ulcerative colitis

Available as: extended-release tablet.

Typical dose

Adults
15 mg once a day (arthritis); higher doses in eczema and IBD.

Typical doses for orientation only. Your prescription, the pack leaflet and local guidance take priority.

Side effects

Common

Often mild and may settle with time

  • Upper respiratory infections
  • Acne
  • Nausea
  • Raised cholesterol
  • Cold sores

Serious — get medical help

Uncommon, but need prompt attention

  • Serious infections
  • Blood clots
  • Heart attack and stroke
  • Cancers
  • Bowel perforation

Warnings

  • Screen for TB before starting
  • Swallow tablets whole

Who should avoid it

  • Active serious infection
  • Active TB
  • Pregnancy
  • Severe liver impairment

Interactions

  • Ketoconazole, clarithromycin — raised levels
  • Rifampicin — lower levels
  • Other immunosuppressants — added infection risk
  • Live vaccines — avoid

Other medicines in the atlas that need care with Upadacitinib, grouped by the reason:

Reduced effectModerateWith Carbamazepine, Efavirenz, Enzalutamide, Griseofulvin, Modafinil and 5 more

Enzyme induction lowers levels of this medicine, which may stop it working.

What's usually done: Monitor effect; dose changes or alternatives may be needed. The effect lasts weeks after stopping the inducer.

Raised drug levelsModerateWith Clarithromycin, Darunavir, Erythromycin, Itraconazole, Lopinavir-ritonavir and 2 more

Blocking CYP3A4 increases levels of this medicine, so side effects become more likely.

What's usually done: A dose reduction, alternative or extra monitoring may be needed.

Check Upadacitinib against your own medicines

Using it safely

Alcohol
Best to limit. Alcohol may add to liver strain.
Food and drink
With or without food.
If you miss a dose
Take when remembered; skip if near the next dose.
Stopping it
Only on advice of your specialist.
Driving
No effect.
Tests and checks
Blood counts; Lipids; Liver tests; Signs of clots
If too much is taken
Seek advice.
Storage
Room temperature.
Legal status
United States: Prescription onlyUnited Kingdom: Prescription-only medicine (POM)India: Schedule HAustralia: Prescription only (Schedule 4)

Pregnancy and breastfeeding

Pregnancy

Usually avoided

Avoid in pregnancy.

Breastfeeding

Usually avoided

Avoid.

Special groups

Kidney disease
Dose adjustment may be needed.
Liver disease
Avoid in severe impairment.
Older adults
Use caution; higher risks.

Brand names

United States
Rinvoq
United Kingdom
Rinvoq
India
Rinvoq
Australia
Rinvoq

Examples only; many generic versions exist. The same brand name can mean different products in different countries.

Common questions

Do I need a prescription for Upadacitinib?

Yes — Upadacitinib is prescription-only in most countries.

Can I take Upadacitinib during pregnancy?

Usually avoided. Avoid in pregnancy. Always check with a doctor or midwife.

How quickly does Upadacitinib work?

Weeks.

Sources and official information

Entry last reviewed October 2026. Compiled from WHO, NHS, FDA/DailyMed, BNF and national formulary information. How we write entries.